ReviewFrontiers in medicine2024
Impact of dry eye disease treatment on patient quality of life.
Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Dry Eye Disease and personality: a systematic review.Frontiers in medicine · 2026Pooled it
- Safety and Effectiveness of Iota-Carrageenan Eye Drops for the Treatment of Dry Eye Disease.Clinical ophthalmology (Auckland, N.Z.) · 2026Trial
- A first-in-human, prospective pilot trial of umbilical cord-derived mesenchymal stem cell eye drops therapy for patients with refractory non-Sjögren's and Sjögren's syndrome dry eye disease.Stem cell research & therapy · 2025Trial
- Sensory impairment, activities of daily living, and multimorbidity in middle-aged and older adults: evidence from the China health and retirement longitudinal study.BMC public health · 2026Article
- Comparative Efficacy and Safety of 0.05% Cyclosporine A and 3% Diquafosol Sodium in Dry Eye Disease: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.Journal of clinical medicine · 2026Review
- Article
- Development of Autologous Serum Ocular Insert for Chronic Dry Eye Disease.Pharmaceutics · 2026Article
- Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling.Frontiers in medicine · 2026Article
- Abnormal meibum is associated with SREBF1 mutation and IFAP Syndrome-2.Experimental eye research · 2026Article
- Knowledge, attitudes, and practices of adult patients with myopia toward refractive surgery and postoperative medications: a cross-sectional study.Frontiers in medicine · 2026Article
- Meibomian Gland Dysfunction and Sex as Risk Factors of Dry Eye Disease in a Cohort of Norwegian 65-year-Olds: A Cross-Sectional Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Abnormal Meibum Is Associated WithmedRxiv : the preprint server for health sciences · 2025Article
- Article
- Electronic device exposure and dry eye symptoms among medical and nonmedical Palestinian university students: a multicenter cross-sectional study of associated factors.BMC ophthalmology · 2025Article
- Oxidative Stress in Dry Eye Disease: A Bibliometric Analysis.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Utilising Narrative Medicine to Identify Key Factors Affecting Quality of Life in Dry Eye Disease: An Italian Multicentre Study.Ophthalmology and therapy · 2024Article
- Understanding the Dry Eye Disease-Related Symptoms in South America: Prevalence and Associated Factors-A Systematic Review.Journal of clinical medicine · 2024Review
- Observational Clinical Investigation Evaluating an Ophthalmic Solution Containing Xanthan Gum and Low Concentration Desonide Phosphate in Dry Eye Disease Treatment.Ophthalmology and therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry eye disease (DED) is a common multifactorial disease affecting a substantial proportion of the population worldwide. Objective tests and subjective symptoms evaluation are necessary to assess DED. Although various treatments have been introduced, accurately evaluating the efficacy of those treatments is difficult because of the disparity between diagnostic tests and patient-reported symptoms. We reviewed the questionnaires used to evaluate DED and the improvements of quality of life with various treatments. In addition, we highlighted the importance of patient-reported outcomes (PRO) assessments for evaluating the effect of DED treatments. Given that the assessment of DED treatment effectiveness substantially relies on individual ocular experiences, acquiring qualitative PRO data is essential for comprehensive evaluation and optimal treatment management. Clinicians should not only focus on improving objective symptoms but also prioritize the well-being of patients in clinical management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.